Background: Anemia is a common complication in chronic kidney disease (CKD), especially in hemodialysis patients, causing fatigue and reduced quality of life. Standard treatments involve iron and erythropoietin (EPO). Ascorbic acid (vitamin C) supports iron metabolism by converting ferric to ferrous iron and enhancing absorption and mobilization. This systematic review and meta-analysis evaluated the effectiveness of ascorbic acid in improving hematologic and iron parameters in adult anemic patients undergoing maintenance hemodialysis. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive search was performed in PubMed, EMBASE, Cochrane, Scopus, Web of Science, CINAHL and Google Scholar through May 2025. Only randomized controlled trials and crossover studies assessing ascorbic acid in adult anemic hemodialysis patients were included. The protocol was registered in the International Prospective Register of Systematic Review (PROSPERO) (CRD420251056337). Primary outcomes were hemoglobin (Hb), ferritin, serum iron, transferrin saturation (TSAT) and total iron-binding capacity (TIBC). Meta-analyses used DerSimonian-Laird random-effects models. Results: Of 479 screened articles, 14 studies were included. Ascorbic acid supplementation was associated with a modest but significant increase in Hb [mean difference (MD) 0.94 g/dL; 95% confidence interval (CI) 0.57 to 1.31; P < .01; I² = 87.2%] and TSAT (MD 6.86%; 95% CI 1.93 to 11.78; P < .01; I² = 96.7%). Ferritin levels showed a slight but significant reduction (MD −65.00 ng/mL; 95% CI −117.20 to −12.80; P = .01; I² = 57.2%), along with a decrease in TIBC (MD −22.54 µg/dL; 95% CI −42.37 to −2.72; P = .03; I² = 76.1%). EPO requirements expressed as units/kg/week were significantly reduced (MD −21.29; 95% CI −27.73 to −14.84; P < .01; I² = 0.0%). No significant changes were observed in serum iron levels or EPO dosage expressed as IU/week. Conclusion: Ascorbic acid supplementation may confer modest hematologic benefits in hemodialysis patients with improvements in Hb, TSAT and iron utilization, and a small reduction in weight-adjusted erythropoiesis-stimulating agent dose. However, the certainty of evidence is low, and long-term safety and patient-centered outcomes remain unestablished.
Background: Endovascular revascularization is a cornerstone therapy for peripheral artery disease (PAD), typically guided by angiography, which may underestimate vessel size and lesion complexity. The clinical benefit of intravascular ultrasound (IVUS) guidance remains uncertain. This systemic review and meta-analysis compare clinical outcomes of IVUS-guided versus angiography-guided endovascular interventions in patients with PAD. Methods: PubMed/MEDLINE, Cochrane, Scopus, Web of Science, EMBASE, and Google Scholar were searched from inception through January 30, 2026, for randomized and observational studies of adults with PAD undergoing endovascular interventions with IVUS versus angiography. Primary outcomes were primary patency, target lesion revascularization (TLR), and late lumen loss. Secondary outcomes included major adverse limb events, amputation, procedural success, and ankle–brachial index improvement. Random-effects meta-analysis was performed using R version 3.4.3. Results: Twenty-three studies encompassing 1,232,018 patients were included. There was no significant difference between IVUS-guided and angiography-guided interventions (RR 1.03; 95% CI 0.81–1.23; p = 0.75; i2 = 60.3%) or freedom from TLR (RR 1.21; 95% CI 0.96–1.54; p = 0.08; I2 = 58.6%). Conclusion: IVUS-guided endovascular interventions in PAD were associated with reduced all-cause mortality, but similar limb-related outcomes compared with angiography guidance. However, these findings are based predominantly on observational evidence. Large-scale randomized trials are needed to confirm these findings and identify patient subgroups that would benefit from IVUS-guided strategies.
30 March 2026 in Archives of Dermatological Research